Evidence map›Paper›PMID 33233407›Full record

ArticleCancers2020

DNA Methylation of

Giovanni Cugliari, Chiara Catalano, Simonetta Guarrera, Alessandra Allione, Elisabetta Casalone, Alessia Russo, Federica Grosso, Daniela Ferrante, Clara Viberti, Anna Aspesi and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Consistent DNA Hypomethylations in Prostate Cancer.International journal of molecular sciences · 2022
    Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Giovanni CugliariDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0002-6080-0718
Chiara CatalanoDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.
Simonetta GuarreraItalian Institute for Genomic Medicine, IIGM, 10060 Candiolo, Italy.ORCID 0000-0003-4400-1817
Alessandra AllioneDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.
Elisabetta CasaloneDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.
Alessia RussoDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0002-5494-2218
Federica GrossoDivision of Medical Oncology, SS. Antonio e Biagio General Hospital, 15121 Alessandria, Italy.
Daniela FerranteUnit of Medical Statistics, Department of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy.
Clara VibertiDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.
Anna AspesiDepartment of Health Sciences, University of Piemonte Orientale, 28100 Novara, Italy.ORCID 0000-0003-4944-0990
Marika SculcoDepartment of Health Sciences, University of Piemonte Orientale, 28100 Novara, Italy.ORCID 0000-0001-8812-3053
Chiara PirazziniDepartment of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40126 Bologna, Italy.ORCID 0000-0001-8248-0295
Roberta LibenerPathology Unit, SS. Antonio e Biagio General Hospital, 15122 Alessandria, Italy.
Dario MirabelliCancer Epidemiology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0003-2312-1342
Corrado MagnaniUnit of Medical Statistics, Department of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy.ORCID 0000-0001-6413-5471
Irma DianzaniDepartment of Health Sciences, University of Piemonte Orientale, 28100 Novara, Italy.
Giuseppe MatulloDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0003-0674-7757
University of Turin · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITAzienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITItalian institute for Genomic Medicine · ITUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive tumor with median survival of 12 months and limited effective treatments. The scope of this study was to study the relationship between blood DNA methylation (DNAm) and overall survival (OS) aiming at a noninvasive prognostic test. We investigated a cohort of 159 incident asbestos exposed MPM cases enrolled in an Italian area with high incidence of mesothelioma. Considering 12 months as a cut-off for OS, epigenome-wide association study (EWAS) revealed statistically significant (

Indexed as

asbestos exposureDNA methylationepigenome-wide analysislymphocyte-to-monocyte ratiomalignant pleural mesotheliomasurvival analysis

Identifiers

PMID33233407
PMCPMC7700347
OpenAlexW3107681343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.